Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of MRG003 in recurrent or metastatic head and neck squamous cell carcinoma
CTR20210328Phase 2Active
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by Hangzhou Miracogen. Started Apr 2021; status: active.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20210328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210328.